Innovent Biologics Targets $5.5B–$6.4B Revenue by 2030 on Global Expansion Push — Innovent Biologics, Inc.

Event summary

Innovent reported H1 2026 revenue of RMB 8.6B (+45% YoY), with product revenue at RMB 8.2B (+57% YoY).
The company aims to reach RMB 35–40B in revenue by 2030, with five molecules in global Phase 3 trials.
Innovent secured $34B in aggregate deal value from 20+ partnered programs over the past 10 months.
Three key assets (IBI363, IBI343, IBI324) target a combined $60B+ TAM in global markets.
Suzhou manufacturing site passed EMA GMP inspection, supporting global supply and CDMO services.

The big picture

Innovent is accelerating its shift from a China-focused biopharma to a global player, leveraging strategic partnerships with Takeda, Lilly, and Pfizer. The company's $34B in deal value underscores its ambition to compete with Western pharma giants in oncology and chronic disease markets. Success hinges on executing its 'dual-engine' strategy of oncology and general biomedicine while navigating regulatory hurdles in key markets.

What we're watching

Global Pipeline Execution: Whether Innovent can advance five molecules into global Phase 3 trials by 2030, particularly IBI363 (PD-1/IL-2α-biased) and IBI343 (CLDN18.2 ADC).
Partnership Leverage: How the $34B in partnered programs will translate into revenue and market share gains in the U.S. and Europe.
Manufacturing Scalability: The pace at which Innovent can expand its 140,000-liter manufacturing capacity to support global demand.